TY - JOUR
T1 - Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
AU - Guccini, Ilaria
AU - Revandkar, Ajinkya
AU - D'Ambrosio, Mariantonietta
AU - Colucci, Manuel
AU - Pasquini, Emiliano
AU - Mosole, Simone
AU - Troiani, Martina
AU - Brina, Daniela
AU - Sheibani-Tezerji, Raheleh
AU - Elia, Angela Rita
AU - Rinaldi, Andrea
AU - Pernigoni, Nicolò
AU - Rüschoff, Jan Hendrik
AU - Dettwiler, Susanne
AU - De Marzo, Angelo M.
AU - Antonarakis, Emmanuel S.
AU - Borrelli, Costanza
AU - Moor, Andreas E.
AU - Garcia-Escudero, Ramon
AU - Alajati, Abdullah
AU - Attanasio, Giuseppe
AU - Losa, Marco
AU - Moch, Holger
AU - Wild, Peter
AU - Egger, Gerda
AU - Alimonti, Andrea
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/1/11
Y1 - 2021/1/11
N2 - Metastases account for most cancer-related deaths, yet the mechanisms underlying metastatic spread remain poorly understood. Recent evidence demonstrates that senescent cells, while initially restricting tumorigenesis, can induce tumor progression. Here, we identify the metalloproteinase inhibitor TIMP1 as a molecular switch that determines the effects of senescence in prostate cancer. Senescence driven either by PTEN deficiency or chemotherapy limits the progression of prostate cancer in mice. TIMP1 deletion allows senescence to promote metastasis, and elimination of senescent cells with a senolytic BCL-2 inhibitor impairs metastasis. Mechanistically, TIMP1 loss reprograms the senescence-associated secretory phenotype (SASP) of senescent tumor cells through activation of matrix metalloproteinases (MMPs). Loss of PTEN and TIMP1 in prostate cancer is frequent and correlates with resistance to docetaxel and worst clinical outcomes in patients treated in an adjuvant setting. Altogether, these findings provide insights into the dual roles of tumor-associated senescence and can potentially impact the treatment of prostate cancer.
AB - Metastases account for most cancer-related deaths, yet the mechanisms underlying metastatic spread remain poorly understood. Recent evidence demonstrates that senescent cells, while initially restricting tumorigenesis, can induce tumor progression. Here, we identify the metalloproteinase inhibitor TIMP1 as a molecular switch that determines the effects of senescence in prostate cancer. Senescence driven either by PTEN deficiency or chemotherapy limits the progression of prostate cancer in mice. TIMP1 deletion allows senescence to promote metastasis, and elimination of senescent cells with a senolytic BCL-2 inhibitor impairs metastasis. Mechanistically, TIMP1 loss reprograms the senescence-associated secretory phenotype (SASP) of senescent tumor cells through activation of matrix metalloproteinases (MMPs). Loss of PTEN and TIMP1 in prostate cancer is frequent and correlates with resistance to docetaxel and worst clinical outcomes in patients treated in an adjuvant setting. Altogether, these findings provide insights into the dual roles of tumor-associated senescence and can potentially impact the treatment of prostate cancer.
KW - FGF1
KW - GDF-15
KW - MMPs
KW - PTEN
KW - TIMP1
KW - docetaxel
KW - prostate cancer metastasis
KW - senescence
KW - senescence-associated secretory phenotype (SASP)
KW - senolytic therapy
UR - http://www.scopus.com/inward/record.url?scp=85096882552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096882552&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2020.10.012
DO - 10.1016/j.ccell.2020.10.012
M3 - Article
C2 - 33186519
AN - SCOPUS:85096882552
SN - 1535-6108
VL - 39
SP - 68-82.e9
JO - Cancer cell
JF - Cancer cell
IS - 1
ER -